

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

|  |  |   |  |
|--|--|---|--|
| Licensee<br><br>1. St. Catherine Hospital, Inc.<br><br>2. 4321 Fir Street<br>East Chicago, IN 46312  |  | In accordance with the letter received<br><b>June 14, 2013,</b><br>3. License number 13-01148-01 is amended in its entirety to read as follows:<br>4. Expiration date July 31, 2015<br>5. Docket No. 030-01590<br>Reference No. |  |
| 6. Byproduct, source, and/or special nuclear material<br><br>A. Any byproduct material permitted by 10 CFR 35.100<br><br>B. Any byproduct material permitted by 10 CFR 35.200<br><br>C. Any byproduct material permitted by 10 CFR 35.300<br><br>D. Cesium-137 permitted by 10 CFR 35.400<br><br>E. Iodine-125 permitted by 10 CFR 35.400<br><br>F. Palladium-103 permitted by 10 CFR 35.400 | 7. Chemical and/or physical form<br><br>A. Any<br><br>B. Any<br><br>C. Any<br><br>D. Sealed sources (3M Model 6500 Series)<br>E. Sealed sources (3M Model Nos. 6711 and 6702; Best Medical International 2301 Series; and Theragenics Corp. Model 125.S06)<br>F. Sealed sources (Best Medical International 2301 Series; Theragenics Corp. Model TheraSeed 200; North American Scientific MED 3633; International Brachytherapy, Inc. Model 1032; OptiSeed; and IsoAid, LLC Model Advantage IAPd-103A) | 8. Maximum amount that licensee may possess at any one time under this license<br><br>A. As needed<br><br>B. As needed<br><br>C. One curie<br><br>D. One curie<br><br>E. One curie<br><br>F. One curie                          |  |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
13-01148-01Docket or Reference Number  
030-01590**Amendment No. 65**

- |  |  |                  |
|--|--|------------------|
| G. Cesium-131 permitted by<br>10 CFR 35.400            | G. Sealed sources (Best Medical<br>International 2301 Series and<br>IsoRay, Inc. CS-1) | G. One curie     |
| H. Samarium-145 permitted by<br>10 CFR 35.400          | H. Sealed sources (Best Medical<br>International 2301 Series)                          | H. One curie     |
| I. Any byproduct material<br>permitted by 10 CFR 31.11 | I. Prepackaged Kits  | I. 5 millicuries |

## 9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. through H., inclusive: Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- I. In vitro studies.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 4321 Fir Street, East Chicago, Indiana.
- 11. The Radiation Safety Officer for this license is James C. Hatten.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Erlinda Roque-Kerekas, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Miquel Gambetta, M.D.

10 CFR 35.100, and 35.200.

John Griep, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Andrej Zajac, M.D.

10 CFR 35.300 and 35.400.

Jong-Yuan Kuo, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
13-01148-01Docket or Reference Number  
030-01590**Amendment No. 65**

|                                |  |
|--------------------------------|--|
| Shawn R. Kenney, M.D.          | 10 CFR 35.100, 35.200, and 31.11.        |
| Jonathon T. Lee, M.D.          | 10 CFR 35.100, 35.200, and 31.11.        |
| Francis X. Roche, M.D.         | 10 CFR 35.100, 35.200, 35.300 and 31.11. |
| Thomas M. Hoess, M.D.          | 10 CFR 35.100, 35.200, and 31.11.        |
| Charles -Lauwanga Okoro, D. O. | 10 CFR 35.200.                           |
| Mikhail Jeha, M.D.             | 10 CFR 35.100, 35.200 and 31.11.         |
| Mohan Kesani, M.D.             | 10 CFR 35.100 and 35.200.                |

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated December 22, 2004;
- B. Facsimile letters dated June 7 and 15, 2005; and,
- C. Letters dated January 2, 2009, April 17, 2009, January 18, 2010, March 8, 2010, January 22, 2013 (with attachment) and March 18, 2013.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 08 2013

By William P. Reichhold  
William P. Reichhold  
Materials Licensing Branch  
Region III